Format

Send to

Choose Destination
Int J Oncol. 2017 Dec;51(6):1739-1746. doi: 10.3892/ijo.2017.4161. Epub 2017 Oct 16.

Antitumoral effect of arsenic compound, sodium metaarsenite (KML001), on multiple myeloma cells.

Author information

1
Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea.
2
Pharmaceutical Division, Komipharm International Co., Ltd., Gyeonggi-do, Republic of Korea.

Abstract

KML001 (sodium metaarsenite;NaAs2O3) is known to have antitumor activity against a variety of cancers. In this study, we examined its effect on multiple myeloma (MM). KML001 reduced the growth of all MM cell lines examined with an IC50 of 5x10‑8 M. Exposure to KML001 (5x10‑8 M) decreased levels of cyclins A/B1/D1/E1, CDK2/4/6 in U266 cells and increased the p21 and p27 levels. Furthermore, p21 became bound to CDK2/4/6, resulting in a reduction of CDK2/4/6 kinase activity. The cleaved forms of Bcl-2, and caspases‑3, ‑8 and ‑9 were detected, and the anti-apoptotic molecule, Bax, also increased. Activation of STAT1/3, NF-κB (p65 and p50 subunits), pAKT and pERK decreased, and p‑PTEN increased. There was also a significant reduction of hTERT at 12 h and upregulation of γ-H2AX and CHK1/2 molecules at 24 h. Thus, KML001 appears to have antitumor activity against MM by inhibiting various oncogenic signaling pathways. It may be useful for treating MM.

PMID:
29039521
DOI:
10.3892/ijo.2017.4161
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Spandidos Publications
Loading ...
Support Center